Quantitative Parameters of Esophageal Varices Based on Computed Tomography May Be Used for Predicting Severe Varices in Patients with Liver Cirrhosis

Shang Wan,Bin Song
DOI: https://doi.org/10.1016/s0168-8278(22)01551-3
IF: 25.7
2022-01-01
Journal of Hepatology
Abstract:computed tomography (Child-Pugh A 242 cases/B 74 cases) who received molecular targeted agents as first-line chemotherapy between July 2009 and February 2019 and measured ammonia levels before ( pre-treatment) and 1 week after treatment ( posttreatment).We examined the incidence and predictors of HE within 2 weeks after treatment.Results: Incidence of HE: Pre-treatment serum ammonia levels elevated significantly compared to post-treatment (56.9 ± 30.6 vs. 79.9 ± 48.3 μmol/L, P < 0.001), and hepatic encephalopathy was observed in 14 patients (4.4%) within 2 weeks after chemotherapy.Risk factors for the development of HE: Multivariate analysis showed that higher pre-treatment ammonia levels (Odds ratio 1.022 [1.008-1.036],P = 0.002) and the greater maximum diameter of portosystemic shunts (Odds ratio 1.094 [1.014-1.179],P = 0.020) were significant predictive factors for the development of HE.Predictive model for the development of HE using a decision-treebased approach: The final selected tree-discriminated cases were classified according to the following 3 subpopulations; low-risk group (ammonia levels <73 μmol/L; development of HE, 0.9%), intermediate-risk group (ammonia levels ≥73 μmol/L and portosystemic shunt diameter <6.2 mm; development of HE, 4.2%), and highrisk group (ammonia levels ≥73 μmol/L and portosystemic shunt diameter ≥6.2 mm; development of HE, 20%). Conclusion:The development of HE after molecular targeted therapy could be clearly risk-segmented according to the ammonia level and the diameter of portosystemic shunts.Therefore, treatment for HE should be considered in cases with higher ammonia levels and large portosystemic shunt before molecular targeted therapy.
What problem does this paper attempt to address?